Stockscreener 앱 받기
628.80
0.79%
5.2625
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Regeneron Pharma strengthens its position in biotech. Focus on long-term growth and innovation - AD HOC NEWS
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program - BioSpace
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme - Pharmaceutical Technology
Element Squared LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA selects seven companies including Eli Lilly and Regeneron for accelerated manufacturing review pilot - grafa.com
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Benzinga
Regeneron opens the week with analyst focus, shares on NASDAQ radar - AD HOC NEWS
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds? - Insider Monkey
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why - Insider Monkey
How the president of Regeneron pursued his American dream - New York Post
Regeneron clears key moving averages, shares trade below consensus targets - Ad-hoc-news.de
Pictet Asset Management Holding SA Sells 30,616 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The EYLEA injection from Regeneron Pharmaceuticals Inc.high-dose eye therapy pushes into diabetic - Ad-hoc-news.de
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment - simplywall.st
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron myasthenia gravis therapy undergoes US and EU review - MSN
why dominant pharmaceutical firms are paying billion dollar premiums for immunology assets - grafa.com
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biotech's Rapid Response to the 2026 Ebola Outbreak: Vaccines, Antibodies, and Therapeutics Advance - Investorideas.com
Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX) - The Globe and Mail
Aethlon Medical tracks Ebola outbreak, readies Hemopurifier talks - Stock Titan
Louisiana State Employees Retirement System Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron highlights robust pipeline progress, shares trade in a neutral technical range - Ad-hoc-news.de
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – GETTEX:RGO - TradingView
Price to earnings forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
The EYLEA Injection from Regeneron Pharmahigh-dose eye therapy targets chronic retinal disease - Ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:REGN) - TradingView
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast - The Manila Times
Regeneron schedules July 30 earnings call and webcast - Stock Titan
REGNUS Forecast — Price Target — Prediction for 2027 - TradingView
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $788 - Moomoo
Assenagon Asset Management S.A. Has $160.54 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prominent construction companies get a portion of Regeneron's $2B Saratoga expansion - The Business Journals
Will Priority-Reviewed Quarterly siRNA gMG Therapy Change Regeneron Pharmaceuticals' (REGN) Narrative? - Yahoo Finance
(REGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
BI Asset Management Fondsmaeglerselskab A S Sells 2,968 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc (REGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Regeneron Pharmaceuticals (REGN) Leans On Pipeline Promise As Undervaluation Case Stays In Focus - simplywall.st
Regeneron (REGN) Advances Cemdisiran for Myasthenia Gravis with Regulatory Approvals - GuruFocus
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Regeneron's Applications for gMG Drug Accepted by FDA and EMA - Yahoo Finance
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Regeneron (REGN) and Alkermes (ALKS) - The Globe and Mail
Regeneron highlights RNAi drug submissions, shares trade in Nasdaq range - AD HOC NEWS
Emerging Stars in Weight Loss: Regeneron and Amgen - Intellectia AI
2 Underrated Weight Loss Stocks to Buy and Hold - The Motley Fool
Regeneron Pharmaceuticals Inc (REGN) Institutional Confidence - TradingKey
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
Regeneron (REGN) Gains Regulatory Milestones for Cemdisiran in g - GuruFocus
0.22%
3.75%
자본화:
|
볼륨(24시간):